Institut Català de la Salut
[Mínguez-Olaondo A, Alves Días P] Neurology Department, Hospital Universitario Donostia-Osakidetza , Neuroscience Area, Biogipuzkoa Health Institute, Donostia, Spain. Athenea Neuroclinics, Donostia, Spain. Department of Medicine and Department of Physical Therapy, Faculty of Health Sciences, University of Deusto, Bilbao and San Sebastian, Spain. [López de Munáin E] Athenea Neuroclinics, Donostia, Spain. Psiquiatric Department, Hospital Bidasoa, Irún, Spain. [Grozeva V] Neurology Practice, Sofia, Bulgaria. [Laspra-Solís C] Department of Psychiatry and Clinical Psychology, University Clinic of Navarra, Madrid, Spain. [Martín Villalba I] Department of Neurology, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Vila-Pueyo M] Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-11-20T09:27:20Z
2024-11-20T09:27:20Z
2024-12
Disability; Migraine; Therapy
Discapacidad; Migraña; Terapia
Discapacitat; Migranya; Teràpia
Background and purpose The US Headache Consortium developed evidence-based guidelines for the treatment of migraine and found grade A evidence in support of behavior therapy (BT). Understanding the mechanisms of BT may improve the management of migraine and reduce its burden. Methods We performed a narrative review to define the current evidence of BT and determine its usefulness in migraine management. Results The information was obtained from 116 publications, with 56 of them retrieved through direct searches in PubMed (2011–2020) and the remainder selected by the authors to complete the content. BT might reduce migraine impact by decreasing the sympathetic nervous system's response to stress and increasing pain tolerance. Acting in headache-related surroundings can be improved, together with headache duration and self-efficacy. Applications such as mobile health and electronic health applications can help to carry out healthier lifestyle patterns. Regarding medication overuse, BT seems to be a good choice, with similar results to pharmacological prophylaxis. Advantages of using BT are the lack of adverse effects and the unrestricted use in children, where BT is postulated to be even more effective than the standardized pharmacopeia. Conclusions BT is an interesting tool that can be used as an add-on therapy in migraine. Through BT, the autonomy and empowerment of migraine patients is enhanced. BT may not cure migraine, but it could help to reduce pain severity perception, disability, and migraine impact, adding an emotive and cognitive approach to the perceptive role of pharmacopeia. Thus, a better approach in migraine, implementing specific therapeutic management, can improve migraine control.
Artículo
Versión publicada
Inglés
Migranya - Tractament; Teràpia de la conducta; DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders; Other subheadings::Other subheadings::/therapy; PSYCHIATRY AND PSYCHOLOGY::Behavioral Disciplines and Activities::Psychotherapy::Behavior Therapy; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos; Otros calificadores::Otros calificadores::/terapia; PSIQUIATRÍA Y PSICOLOGÍA::disciplinas y actividades conductuales::psicoterapia::terapia conductista
Wiley
European Journal of Neurology;31(12)
https://doi.org/10.1111/ene.16414
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]